Impact of HBV Integration on Hepatocellular Carcinoma After Long-Term Antiviral Therapy

References

• Rumgay H, Ferlay J, de Martel C, et al. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. 2022;161:108–118. doi:10.1016/j.ejca.2021.11.023
   PubMed Web of Science ®Google Scholar
• Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598–1606. doi:10.1016/j.jhep.2022.08.021
   PubMed Web of Science ®Google Scholar
• Cong WM, Bu H, Chen J, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol. 2016;22(42):9279–9287. doi:10.3748/wjg.v22.i42.9279
   PubMed Web of Science ®Google Scholar
• Yang Y, Lu S. Guideline for stratified screening and surveillance of primary liver cancer(2020 Edition). Zhonghua Gan Zang Bing Za Zhi. 2021;29(1):25–40. doi:10.3760/cma.j.cn112152-20201109-00970
   PubMedGoogle Scholar
• Liu Y, Zheng J, Hao J, et al. Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019. Cancer Med. 2022;11(5):1310–1323. doi:10.1002/cam4.4551
   PubMed Web of Science ®Google Scholar
• Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9(4):452–463. doi:10.21037/hbsn-20-480
   PubMed Web of Science ®Google Scholar
• Renne SL, Sarcognato S, Sacchi D, et al. Hepatocellular carcinoma: a clinical and pathological overview. Pathologica. 2021;113(3):203–217. doi:10.32074/1591-951x-295
   PubMed Web of Science ®Google Scholar
• Chow N, Wong D, Lai CL, et al. Effect of antiviral treatment on hepatitis B virus integration and hepatocyte clonal expansion. Clin Infect Dis. 2023;76(3):e801–e809. doi:10.1093/cid/ciac383
   PubMed Web of Science ®Google Scholar
• Russo FP, Zanetto A, Pinto E, et al. Hepatocellular carcinoma in chronic viral hepatitis: where do we stand? Int J Mol Sci. 2022;23(1):500. doi:10.3390/ijms23010500
   PubMed Web of Science ®Google Scholar
• Jang JW, Kim HS, Kim JS, et al. Distinct patterns of HBV Integration and TERT alterations between in tumor and non-tumor tissue in patients with hepatocellular carcinoma. Int J Mol Sci. 2021;22(13):7056. doi:10.3390/ijms22137056
   PubMed Web of Science ®Google Scholar
• Chen W, Zhang K, Dong P, et al. Noninvasive chimeric DNA profiling identifies tumor-originated HBV integrants contributing to viral antigen expression in liver cancer. Hepatol Int. 2020;14(3):326–337. doi:10.1007/s12072-020-10016-2
   PubMed Web of Science ®Google Scholar
• Zhao LH, Liu X, Yan HX, et al. Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma. Nat Commun. 2016;7:12992. doi:10.1038/ncomms12992
   PubMed Web of Science ®Google Scholar
• Hu B, Huang W, Wang R, et al. High Rate of Detection of Human ESPL1-HBV S fusion gene in patients with HBV-related liver cancer: a Chinese case-control study. Anticancer Res. 2020;40(1):245–252. doi:10.21873/anticanres.13946
   PubMed Web of Science ®Google Scholar
• Pollicino T, Caminiti G. HBV-integration studies in the clinic: role in the natural history of infection. Viruses. 2021;13(3):368. doi:10.3390/v13030368
   PubMed Web of Science ®Google Scholar
• Tu T, Budzinska MA, Shackel NA, Urban S. HBV DNA integration: molecular mechanisms and clinical implications. Viruses. 2017;9(4):75. doi:10.3390/v9040075
   PubMed Web of Science ®Google Scholar
• Hu B, Wang R, Fu J, et al. Integration of hepatitis B virus S gene impacts on hepatitis B surface antigen levels in patients with antiviral therapy. J Gastroenterol Hepatol. 2018;33(7):1389–1396. doi:10.1111/jgh.14075
   PubMed Web of Science ®Google Scholar
• You H, Sun YM, Zhang MY, et al. Interpretation of the essential updates in guidelines for the prevention and treatment of chronic hepatitis B (Version 2022). Zhonghua Gan Zang Bing Za Zhi. 2023;31(4):385–388. doi:10.3760/cma.j.cn501113-20230324-00127
   PubMedGoogle Scholar
• Lin SY, Zhang A, Lian J, et al. Recurrent HBV integration targets as potential drivers in hepatocellular carcinoma. Cells. 2021;10(6):1294. doi:10.3390/cells10061294
   PubMed Web of Science ®Google Scholar
• Li W, Zeng X, Lee NP, et al. HIVID: an efficient method to detect HBV integration using low coverage sequencing. Genomics. 2013;102(4):338–344. doi:10.1016/j.ygeno.2013.07.002
   PubMed Web of Science ®Google Scholar
• Jiang Z, Jhunjhunwala S, Liu J, et al. The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res. 2012;22(4):593–601. doi:10.1101/gr.133926.111
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang H, Cheng X, et al. Liver biopsy of chronic hepatitis B patients indicates HBV integration profile may complicate the endpoint and effect of entecavir treatment. Antiviral Res. 2022;204:105363. doi:10.1016/j.antiviral.2022.105363
   PubMed Web of Science ®Google Scholar
• Li W, Cui X, Huo Q, et al. Profile of HBV integration in the plasma DNA of hepatocellular carcinoma patients. Curr Genomics. 2019;20(1):61–68. doi:10.2174/1389202919666181002144336
   PubMed Web of Science ®Google Scholar
• D’Souza S, Lau KC, Coffin CS, Patel TR. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J Gastroenterol. 2020;26(38):5759–5783. doi:10.3748/wjg.v26.i38.5759
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang X, Ge X, et al. CMSS1::FLT1 rearrangement leads to ligand-independent activation of FLT1 signaling in acute myeloid leukemia. Am J Hematol. 2023;98(12):E380–e382. doi:10.1002/ajh.27108
   PubMed Web of Science ®Google Scholar
• Sheng H, Jiang Y, Li L. SHANK2-FGFR1: a Novel FGFR1 rearrangement in a patient with intestinal adenocarcinoma. J Coll Physicians Surg Pak. 2021;31(11):1384–1385. doi:10.29271/jcpsp.2021.11.1384
   PubMed Web of Science ®Google Scholar
• Xu L, Li P, Hao X, et al. SHANK2 is a frequently amplified oncogene with evolutionarily conserved roles in regulating Hippo signaling. Protein Cell. 2021;12(3):174–193. doi:10.1007/s13238-020-00742-6
   PubMed Web of Science ®Google Scholar
• Fan M, Xiong X, Han L, et al. SERPINA5 promotes tumour cell proliferation by modulating the PI3K/AKT/mTOR signalling pathway in gastric cancer. J Cell Mol Med. 2022;26(18):4837–4846. doi:10.1111/jcmm.17514
   PubMed Web of Science ®Google Scholar
• Jing Y, Jia D, Wong CM, et al. SERPINA5 inhibits tumor cell migration by modulating the fibronectin-integrin β1 signaling pathway in hepatocellular carcinoma. Mol Oncol. 2014;8(2):366–377. doi:10.1016/j.molonc.2013.12.003
   PubMed Web of Science ®Google Scholar
• Cui X, Wei W, Wang C, et al. Studies on the correlation between mutation and integration of HBV in hepatocellular carcinoma. Biosci Rep. 2020;40(8). doi:10.1042/BSR20201988
   Google Scholar
• Zhang D, Zhang K, Protzer U, Zeng C. HBV integration induces complex interactions between host and viral genomic functions at the insertion site. J Clin Transl Hepatol. 2021;9(3):399–408. doi:10.14218/jcth.2021.00062
   PubMed Web of Science ®Google Scholar